On Saturday, October 24, 2009, President Obama, recognizing the rapid increase of Influenza A, H1N1 illnesses across the United States, declared the 2009 H1N1 influenza pandemic a national emergency.
Also, on October 22, 2009 the EPA released guidance regarding H1N1 stating that products currently registered with claims for effectiveness against influenza A viruses will also be effective against the Pandemic 2009 Influenza A, H1N1 flu strain and other influenza A virus strains on hard, non-porous surfaces.
Lonza Microbial Control is pleased to announce it has numerous disinfectants available that are registered with influenza A virus claims. According to EPA, these products will also combat the Pandemic 2009 Influenza A H1N1 flu strain.
Also, Lonza’s Tools & Services business offer industry recognized H1N1 testing for formulators who promote and offer products with this specific claim. Our labs conduct testing by ASTM E1053-97 (US) and by EN 14476:2005 with Influenza A virus (H1N1) A/WS/33, ATCC strain VR-1520.
The 2009 outbreak of Influenza A virus, H1N1 has many people concerned about their health. The prevention of its transmission has become a priority for suppliers of disinfectant products. A label claim of efficacy against Influenza virus A, H1N1 is a critical product enhancement required to achieve this high priority target for customers.
To reach a customer service representative regarding our formulations, please call Robert Kreminski (201) 316-9366 or email him.
To learn more about Lonza Microbial Control’s cost effective, confidential testing services, please contact firstname.lastname@example.org in the US and email@example.com in EMEA.
Additional information regarding Influenza A H1N1 is available at:
US Gov flu site
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.
For further Information:
Global Marketing Director Hygiene & Preservation
Life Science Ingredients - Microbial Control
CH-4002 Basel, Switzerland
Tel Switzerland: +41 61 316 83 81
Tel United States: +1 201 316 9412
David E. Gregg
Regional Marketing Director-Hygiene & Preservation
25 Commerce Drive
Allendale, NJ 07401
Sr. Corporate Communications Manager
Lonza America, Inc.
90 Boroline Rd.
Allendale, NJ 07401